Surmodics | SRDX - Gross Profit On Sales


Surmodics reported $20.08M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Align Technology USD 736.59M 53M Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Artivion USD 73.14M 1.25M Dec/2025
Baxter International USD 891M 314M Mar/2026
Boston Scientific USD 3.61B 64M Mar/2026
EDAP TMS EUR 5.97M 850K Sep/2025
Edwards Lifesciences USD 1.29B 59.4M Mar/2026
Haemonetics USD 202.39M 7.64M Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
J&J USD 17.24B 642M Mar/2026
Merit Medical Systems USD 184.8M 10.56M Mar/2026
Mesa Laboratories USD 39.75M 4.3M Dec/2024
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Option Care Health USD 262.01M 20.88M Mar/2026
Stryker USD 3.81B 675M Mar/2026
Surmodics USD 20.08M 31.62M Jun/2025
Trinity Biotech USD 6.47M 1.59M Sep/2025